A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.
Also called NCT06168409
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 218 participants
- Sponsor
- Registry
-
NCT06168409 -
2023-507640-36-00
-
- Other papers using this trial's data
- Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Malaysia, Philippines, Poland, Saudi Arabia, Slovakia, South Africa, Spain, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT06168409. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-08-17 (actual). Results posted on 2026-08-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
- Acronym
- Bax24
- Condition
- Resistant Hypertension
- Intervention (Drug)
- Baxdrostat
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06168409- Content hash
f118642c112c4bdd1d2441defcbea2fe4b26d4fc3dda9088690de1de0d3f24ff